Enterprise Value
0.00
Cash
123.6M
Avg Qtr Burn
N/A
Short % of Float
0.03%
Insider Ownership
12.21%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Lenmeldy (atidarsagene autotemcel) (OTL-200) (ex vivo autologous gene therapy) Details Rare diseases, Rare genetic disease, Metachromatic leukodystrophy | Approved Quarterly sales | |
OTL-203 (ex vivo autologous gene therapy) Details Metabolic disorder, Mucopolysaccharidosis Type 1 | Phase 2 Data readout | |
OTL-201 (ex vivo autologous gene therapy) Details Metabolic disorder, Eye disease , Mucopolysaccharidosis type IIIA, Sanfilippo Syndrome | Phase 1/2 Update | |
OTL-103 (ex vivo autologous gene therapy) Details X-Linked severe combined immunodeficiency, Autoimmune disease | Failed Discontinued |